Skip to main content
. 2021 Sep 14;27(34):5753–5763. doi: 10.3748/wjg.v27.i34.5753

Table 2.

Baseline characteristics of the patients


Overall, n = 417
No/mild fibrosis, n = 261
Advanced fibrosis, n = 156
P value
Age (yr) 40.54 ± 10.95 39.42 ± 11.39 42.41 ± 9.94 0.007
Male, n (%) 354 (84.9) 219 (83.9) 135 (86.5) 0.468
BMI (kg/m2) 25.48 ± 2.66 25.51 ± 2.56 25.42 ± 2.83 0.757
Diabetes mellitus, n (%) 82 (19.7) 46 (17.6) 36 (23.1) 0.175
Hypertension, n (%) 42 (10.1) 30 (11.5) 12 (7.7) 0.212
ALB (g/L) 42.53 ± 4.96 43.65 ± 5.14 40.65 ± 3.98 < 0.001
GLO (g/L) 29.88 ± 14.11 29.11 ± 6.00 31.13 ± 21.53 0.160
ALT (U/L) 133.07 ± 199.05 126.93 ± 151.37 143.33 ± 260.27 0.416
AST (U/L) 70.69 ± 85.14 63.24 ± 62.19 83.17 ± 112.77 0.021
GGT (U/L) 89.64 ± 109.58 88.75 ± 117.46 91.11 ± 95.28 0.832
FPG (mmol/L) 5.34 ± 1.42 5.28 ± 1.20 5.45 ± 1.73 0.251
Cr (μmol/L) 73.41 ± 13.71 74.00 ± 13.50 72.41 ± 14.07 0.273
UA (μmol/L) 368.49 ± 82.08 377.02 ± 83.87 353.77 ± 76.98 0.007
TG (mmol/L) 1.67 ± 1.12 1.78 ± 1.45 1.48 ± 0.71 0.016
HDL-C (mmol/L) 1.12 ± 0.30 1.12 ± 0.29 1.12 ± 0.33 0.959
PLT (× 109/L) 204.00 ± 64.22 221.00 ± 62.76 175.52 ± 56.22 < 0.001
FIB-4 1.48 ± 1.64 1.19 ± 1.65 1.97 ± 1.49 < 0.001
APRI 1.03 ± 1.72 0.84 ± 1.33 1.34 ± 2.19 0.003
NFS -2.16 ± 1.38 -2.56 ± 1.24 -1.50 ± 1.33 < 0.001
BARD (%) < 0.001
0 209 (50.1) 145 (55.6) 64 (41.0)
1 86 (20.6) 59 (22.6) 27 (17.3)
2 92 (22.1) 48 (18.4) 44 (28.2)
3 25 (6.0) 8 (3.1) 17 (10.9 )
4 5 (1.2) 1 (0.4) 4 (2.6)

ALB: Albumin; ALT: Alanine aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; AST: Aspartate aminotransferase; BARD: Body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score; BMI: Body mass index; Cr: Creatinine; FIB-4: Fibrosis-4 index; FPG: Fasting plasma glucose; GGT: γ-Glutamyl transpeptidase; GLO: Globulin; HDL-C: High-density lipoprotein cholesterol; NFS: Non-alcoholic fatty liver disease fibrosis score; PLT: Platelet; TG: Triglyceride; UA: Uric acid.